Marinus Pharmaceuticals Inc has a consensus price target of $13.9, established from looking at the 40 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Truist Securities on May 9, 2024, May 7, 2024, and April 17, 2024. With an average price target of $10.67 between HC Wainwright & Co., HC Wainwright & Co., and Truist Securities, there's an implied 702.01% upside for Marinus Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/09/2024 | Buy Now | 727.07% | HC Wainwright & Co. | Douglas Tsao | → $11 | Reiterates | Buy → Buy | Get Alert |
05/07/2024 | Buy Now | 727.07% | HC Wainwright & Co. | Douglas Tsao | $27 → $11 | Maintains | Buy | Get Alert |
04/17/2024 | Buy Now | 651.88% | Truist Securities | Joon Lee | $25 → $10 | Maintains | Buy | Get Alert |
04/16/2024 | Buy Now | 50.38% | Baird | Brian Skorney | $20 → $2 | Downgrade | Outperform → Neutral | Get Alert |
04/16/2024 | Buy Now | 1930.08% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
04/15/2024 | Buy Now | 125.56% | RBC Capital | Brian Abrahams | $24 → $3 | Downgrade | Outperform → Sector Perform | Get Alert |
04/10/2024 | Buy Now | 2005.26% | Cantor Fitzgerald | Charles Duncan | → $28 | Reiterates | Overweight → Overweight | Get Alert |
03/26/2024 | Buy Now | 1930.08% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
03/07/2024 | Buy Now | 576.69% | Oppenheimer | Jay Olson | $9 → $9 | Maintains | Perform | Get Alert |
03/06/2024 | Buy Now | 1704.51% | RBC Capital | Brian Abrahams | → $24 | Reiterates | Outperform → Outperform | Get Alert |
03/06/2024 | Buy Now | 1930.08% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
12/05/2023 | Buy Now | 1930.08% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
11/08/2023 | Buy Now | 1779.7% | Truist Securities | Joon Lee | $32 → $25 | Maintains | Buy | Get Alert |
09/21/2023 | Buy Now | 2005.26% | Cantor Fitzgerald | Charles Duncan | → $28 | Reiterates | Overweight → Overweight | Get Alert |
09/20/2023 | Buy Now | 1478.95% | RBC Capital | Brian Abrahams | $20 → $21 | Maintains | Outperform | Get Alert |
09/20/2023 | Buy Now | 1930.08% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | Buy Now | 1930.08% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | Buy Now | 1403.76% | RBC Capital | Brian Abrahams | $21 → $20 | Maintains | Outperform | Get Alert |
08/11/2023 | Buy Now | 2306.02% | Truist Securities | Joon Lee | $42 → $32 | Maintains | Buy | Get Alert |
08/11/2023 | Buy Now | 877.44% | Ladenburg Thalmann | Michael Higgins | $17 → $13 | Maintains | Buy | Get Alert |
08/11/2023 | Buy Now | 1403.76% | Baird | Brian Skorney | $24 → $20 | Maintains | Outperform | Get Alert |
08/11/2023 | Buy Now | 952.63% | Oppenheimer | Jay Olson | → $14 | Downgrade | Outperform → Perform | Get Alert |
06/23/2023 | Buy Now | 2005.26% | Cantor Fitzgerald | Charles Duncan | $28 → $28 | Reiterates | Overweight → Overweight | Get Alert |
06/14/2023 | Buy Now | 1930.08% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
05/30/2023 | Buy Now | 1253.38% | JMP Securities | Jason West | → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
05/12/2023 | Buy Now | 3057.89% | Truist Securities | Joon Lee | $50 → $42 | Maintains | Buy | Get Alert |
05/12/2023 | Buy Now | 1930.08% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
04/25/2023 | Buy Now | 1554.14% | RBC Capital | Brian Abrahams | → $22 | Reiterates | → Outperform | Get Alert |
04/25/2023 | Buy Now | 952.63% | Oppenheimer | Jay Olson | $12 → $14 | Maintains | Outperform | Get Alert |
03/08/2023 | Buy Now | 2005.26% | Cantor Fitzgerald | Charles Duncan | → $28 | Reiterates | → Overweight | Get Alert |
The latest price target for Marinus Pharma (NASDAQ: MRNS) was reported by HC Wainwright & Co. on May 9, 2024. The analyst firm set a price target for $11.00 expecting MRNS to rise to within 12 months (a possible 727.07% upside). 25 analyst firms have reported ratings in the last year.
The latest analyst rating for Marinus Pharma (NASDAQ: MRNS) was provided by HC Wainwright & Co., and Marinus Pharma reiterated their buy rating.
There is no last upgrade for Marinus Pharma.
The last downgrade for Marinus Pharmaceuticals Inc happened on April 16, 2024 when Baird changed their price target from $20 to $2 for Marinus Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marinus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marinus Pharma was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.
While ratings are subjective and will change, the latest Marinus Pharma (MRNS) rating was a reiterated with a price target of $0.00 to $11.00. The current price Marinus Pharma (MRNS) is trading at is $1.33, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.